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Abstract 
Objectives 
Review outcomes of transcatheter closure of patent ductus arteriosus (PDA), role of PDA shape 
and changes in practice over time.  
Methods 
Retrospective analysis of patient files and clinic database performed on children who had 
transcatheter PDA closure at Chris Hani Baragwanath Hospital between 01/01/1993 and 
30/06/2008.  
Results 
Over 15 years, 1254 PDAs were diagnosed, of which 293 required closure (167 with surgery and 
139 transcatheter). Median age at transcatheter closure was 1.8 years (IQR=1-4.5years); 66.2% 
were female (92/139). Mean PDA diameter was 3.2mm (sd=1.6mm), with an average 2:1 shunt. 
Transcatheter closure was performed using COOK® Flipper coils (n= 93; 18 required multiple coils) 
or Amplatzer™ devices (n=46: 37 with ADO1, 8 AVP and 1 ADO2). Repeat procedures were 
needed in 20 children: Early occlusion rates for coils were 52% (39/75); late occlusion occurred in 
90.6% (68/75). Amplatzer™ devices, available since 2003, are now overwhelmingly used. For 
ADOs, early occlusion rates were 94.3% (33/35) with 100% late occlusion. Successful closures 
were associated with PDA shape, with 88% closed with type A and E,  50% type B, 28% type C 
and 0% type D. Surgical closure reduced over time: from 94 weeks (1993–1997), to 40 weeks  
(1998–2002) and 32 weeks(2003–2008).  
Conclusion 
Transcatheter PDA occlusion is safe and effective in this setting, with outcomes similar to reports 
elsewhere. Shape and size of PDAs are important determinants of device selection and procedure 
outcome. Transcatheter occlusion helps minimise surgical waiting lists. Overall findings support 
more widespread use of this procedure in similar settings.  
 
 
 
 
 
 
 
 
  
v 
 
Table of Contents 
Declaration ................................................................................................................... i 
Acknowledgements ..................................................................................................... iii 
Abstract ....................................................................................................................... iv 
Table of Contents ......................................................................................................... v 
List of Figures ............................................................................................................... vi 
List of Tables ............................................................................................................... vii 
List of Publications arising from this Research Report ................................................. viii 
List of Abbreviations ..................................................................................................... ix 
Chapter 1 - Introduction ............................................................................................... 1 
Chapter 2 - Methodology .............................................................................................. 7 
2.1 Objectives ...................................................................................................................... 7 
2.2 Study design and population .......................................................................................... 7 
2.3 Procedure ...................................................................................................................... 7 
2.3.1 Implantation details.......................................................................................................... 7 
2.4 Data / Study variables: ................................................................................................. 10 
2.4.1 Data collection: ............................................................................................................... 10 
2.4.2 Study variables ............................................................................................................... 10 
2.5 Statistics and Data analysis........................................................................................... 13 
2.6 Ethics Approval ............................................................................................................ 13 
Chapter 3 - Results ..................................................................................................... 14 
3.1 Patient Characteristics ................................................................................................. 14 
3.2 Patent ductus arteriosus characteristics ........................................................................ 15 
3.2.1 Size and shape: ............................................................................................................... 15 
3.2.2 Haemodynamics and Flouroscopy time: ........................................................................ 16 
3.3 Procedure and patient outcomes .................................................................................. 18 
3.3.1 Combined outcome ........................................................................................................ 18 
3.3.2 COOK® Coils: ................................................................................................................... 19 
3.3.3 Amplatzer™ devices:....................................................................................................... 20 
3.3.4 Outcome and shape ....................................................................................................... 22 
3.3.5 Time to complete closure ............................................................................................... 24 
3.3.6 Changes over time .......................................................................................................... 25 
3.3.7 Complications: ................................................................................................................ 28 
Chapter 4 - Discussion ................................................................................................ 30 
Chapter 5 - Conclusions .............................................................................................. 36 
References ................................................................................................................. 37 
Appendix .................................................................................................................... 39 
DATA Sheet .............................................................................................................................. 39 
Turnitin Report ........................................................................................................................ 41 
Ethics Clearance ....................................................................................................................... 42 
 
  
vi 
 
List of Figures 
Figure 1.1: MReye Flipper PDA coil
(12)
 ......................................................................................................... 4 
Figure 1.2: Amplatzer Duct Occluder 1
(13)
 .................................................................................................... 4 
Figure 1.3: Amplatzer Vascular Plug 1
(14)
 ..................................................................................................... 5 
Figure 1.4: Amplatzer Duct Occluder II
(15)
 .................................................................................................... 5 
Figure 2.1:Amplatzer Duct Occluder 1 Dimensions and sizing chart
(23)
 ........................................................ 9 
Figure 2.2: Krichenko Classification of PDA shape
(24)
 ................................................................................. 11 
Figure 3.1: Graph describing outcome of first procedure .......................................................................... 18 
Figure 3.2: Outcome of initially failed procedures .................................................................................... 19 
Figure 3.3: Flow chart describing the patients who had PDA coiling and their outcome ........................... 20 
Figure 3.4: Algorithm describing patients who had PDA closure with an Amplatzer device ...................... 21 
Figure 3.5: Outcomes - Coil vs Amplatzer devices at first procedure ......................................................... 22 
Figure 3.6: Effect of PDA shape on outcome at first procedure ................................................................. 22 
Figure 3.7: Time to complete closure ........................................................................................................ 24 
Figure 3.8: Device usage changes over time .............................................................................................. 25 
Figure 3.9: Number of patients requiring a repeat procedure to close the PDA ........................................ 26 
Figure 3.10: Median waiting time in weeks over the study period ............................................................ 27 
Figure 3.11: Number of PDA's ligated per year over the study period ....................................................... 27 
Figure 4.1: Comparison of PDA closure with coils between our results and the review reported by Galal et 
al ..................................................................................................................................................... 31 
Figure 4.2: Comparison of PDA closure with ADO between our results and the review reported by Galal et 
al ..................................................................................................................................................... 32 
Figure 4.3: Comparison of closure rates with the ADO between our centre and the results as reported by 
Pass et al .......................................................................................................................................... 33 
Figure 4.4: Comparison of PDA closure with the ADO between our centre and the results as reported by 
Pass et al .......................................................................................................................................... 33 
 
  
vii 
 
List of Tables 
Table 3.1: Patient Characteristics .............................................................................................................. 14 
Table 3.2: Characteristics of Patent Ductus Arteriosus in study population .............................................. 15 
Table 3.3: Haemodynamic measurements and comparison between coil and Amplatzer group ............... 16 
Table 3.4: Device usage for each PDA shape at initial procedure .............................................................. 23 
Table 3.5: Complications at first procedure relating to PDA shape............................................................ 29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
List of Publications arising from this Research Report 
 
 Presented as a poster at the World congress of Paediatric Cardiology and Cardiac 
Surgery in Cairns Australia 2009  
 Presented data as an oral presentation at the South African Heart Association 
congress in 2008 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ix 
 
List of Abbreviations 
 
PDA:   Patent Ductus Arteriosus 
DA:   Ductus Arteriosus 
ADO:   Amplatzer™ Duct Occluder 
LA:   Left Atrium 
AO:   Aorta 
LA:Ao :  Left Atrium to Aortic ratio 
SVT:   Supraventricular tachycardia 
CHBAH:  Chris Hani Baragwanath Academic Hospital
1 
 
Chapter 1 - Introduction  
The patent ductus arteriosus (PDA) is a common congenital heart lesion with isolated 
PDAs accounting for between 6-11% of all congenital heart defects
(1)
. PDAs are relatively 
easy to diagnose, and as new devices become available the majority can be effectively and 
safely closed without surgery, preventing not only the complications of the PDA itself but 
also some of the morbidity associated with surgery
(1)
. Surgical closure has been the 
standard management of PDAs. However more recently, transcatheter closure methods 
have superseded surgery for most PDAs, and increasingly so.  
The ductus arteriosus (DA) is a large vessel that is an essential part of the foetal 
circulation. The DA allows blood leaving the right ventricle to bypass the lungs and flow 
directly from the pulmonary trunk into the descending aorta
(2)
. Shortly after birth, 
constriction of the DA, results in functional closure. Functional closure is usually complete 
within hours of birth; complete anatomical closure is achieved by two-to three weeks. 
Failure of the DA to close results in a PDA.  
Prematurity predisposes to persistent patency of the ductus; the shorter the gestation the 
higher the incidence of PDA. According to A. Rudolph: “More than 80% of infants 
weighing less than 750 grams have patency of the ductus arteriosus beyond the third day 
after birth.” (3) Numerous factors underlie the high incidence of PDA in premature infants, 
including immaturity of ductal tissue, increased circulating prostaglandins and hypoxia, to 
which these infants are predisposed
(3)
. 
Persistent PDA in term infants, who are not hypoxic after birth, is likely a result of 
structural or biochemical abnormalities of the ductus arteriosus, which interfere with 
physiological constriction. There are a number of theories as to the possible biochemical 
and structural reasons for persistent patency of the DA. Congenital rubella has been shown 
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to result in an increased incidence of PDA. There is also a possible genetic basis with some 
families showing recurrences
(3)
.  
Persistent patency of the DA results in left to right shunting of blood from the aorta to the 
pulmonary arteries. This results in increased pulmonary blood flow, which is the first step 
to the resulting morbidity and mortality caused by the PDA. The size of the left to right 
shunt determines the severity of the symptoms and the progression (if untreated) to 
irreversible pulmonary hypertension, Eisenmengers Syndrome and death. The size of the 
shunt is firstly dependant on the size of the PDA, however the relationship between the 
pulmonary and systemic vascular resistances also play an important role in determining the 
volume of blood shunted
(3)
. Together, these factors determine the clinical presentation and 
progression.  
The initial effect of increased pulmonary flow is volume overload of the left atrium and 
left ventricle resulting in left-sided cardiac failure. This manifests as failure to thrive, 
excessive sweating while feeding, poor feeding, recurrent chest infections and decreased 
effort tolerance. The increased flow leads to changes in the pulmonary vasculature, which 
together with the increased left atrial pressure, results in increased pulmonary pressures. 
The pulmonary pressures continue to rise and eventually become equal to systemic 
pressures. At this point, the shunting stops and the child is seen to improve. The pulmonary 
pressures continue to increase and right to left shunting begins. Changes in the pulmonary 
vasculature become irreversible – once this point is reached it is known as Eisenmengers 
Syndrome. For children with Eisenmengers syndrome, closure of the PDA is 
contraindicated and treatment becomes predominately supportive. Progression of a child 
with a PDA to Eisenmengers Syndrome is completely unacceptable, and reflects several 
failures in child health services.  
Large PDAs tend to result in more severe symptoms and signs with rapid progression of 
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the disease, small PDAs may remain undiagnosed, even lifelong. The small PDA however, 
despite not causing pulmonary hypertension, can have devastating consequences in the 
form of infective endocarditis. 
Early recognition and treatment of the PDA is critical for preventing these disastrous and 
avoidable outcomes. 
Broadly, there are two options for closure of PDAs: surgical or transcatheter occlusion. 
Transcatheter closure involves the insertion of a device, through a catheter into the PDA 
from peripheral vessels such as the femoral artery or vein. The indications for closure are 
the same for both treatment options. There are factors that would make one method more 
appropriate than the other,
(1, 4)
 for example; the shape of the PDA, the size of the PDA, 
pulmonary pressures and pulmonary resistance. Since the introduction of echocardiography 
with colour Doppler the entity of a ‘silent’ DA has been described(5). This is a PDA that, in 
the absence of colour Doppler, would have remained undiagnosed. The current expert 
recommendations are that a ‘silent’ ductus does not require closure(1, 5). 
Surgical closure of the PDA has been available for many years, with the first report of 
surgical ligation by Gross and Hubbard in 1939
(6)
. This method then became the standard 
management
(7)
. Only in the last few decades has this been challenged by transcatheter 
options. More recently transcatheter PDA closure has become the preferred alternative to 
surgery
(8, 9)
. 
The first transcatheter options for closure of the PDA were described by Porstmann and co-
workers in 1967
(10)
. Since then several devices have been designed for transcatheter 
closure of the PDA. At the time of the study available devices were coils e.g. detachable 
MReye® Flipper® PDA coils, Gianturco coils, pfm medical PDA coil, Nit-Occlud® PDA 
coils, the Gianturco-Grifka vascular occlusion device, and the range of Amplatzer™ 
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devices (Amplatzer™ Duct Occluders, Amplatzer™ Vascular Plug and the Amplatzer™ 
ASD and VSD occluders). In the last few years the number of available devices has grown 
significantly. They range from close copies of the Amplatzer™ design, to devices with 
different shapes and release mechanisms (Ceraflex and Occlutec). In addition to these new 
devices the Amplatzer™ range has expanded offering devices with different shapes and 
even a range to close very small PDA’s(11). 
 
Figure 1.1: MReye Flipper PDA coil
(12) 
 
 
 
 
Figure 1.2: Amplatzer Duct Occluder 1
(13)
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Figure 1.3: Amplatzer Vascular Plug 1
(14)
 
 
 
Figure 1.4: Amplatzer Duct Occluder II
(15)
 
 
At the time of the study the detachable COOK® PDA coils were widely used in small 
PDAs (<2.5 mm)
(8, 9, 16, 17)
. The Amplatzer™ Devices have become increasingly popular 
for moderate to large PDAs (>2.5 mm)
(8, 9)
. These were first implanted in 1996 
(16)
 and 
have since been shown to be safe, effective and relatively easy to use
(9, 18-20)
. The spectrum 
of PDAs amenable to transcatheter closure also continues to increase. With advances in 
closure technologies, only very small infants with large symptomatic PDAs, and PDAs 
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with unfavourable anatomy or failed device closure are candidates for surgical closure
(4, 9)
.  
In this study I review the transcatheter closure of the PDA’s at Chris Hani Baragwanath 
Academic hospital over a fifteen-year period which includes the introduction of the 
Amplatzer™ range of devices to our setting. 
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Chapter 2 - Methodology 
2.1 Objectives  
The objectives of this research report are: 
 To assess transcatheter management of PDA at Chris Hani Baragwanath Academic 
Hospital, over a fifteen year period. 
 To assess the effects of the size and shape on the transcatheter management of the 
PDA. 
 Compare outcome of transcatheter procedures in our setting with outcomes 
recorded in the literature by other centres.  
 Describe the demographic profile of patients with PDAs in our setting. 
Hypothesis 
1. Shape and size are both important factors determining which device is selected for 
closing a particular PDA, and for closure outcome. 
2. Transcatheter occlusion of PDAs is safe and effective in our setting 
2.2 Study design and population 
A retrospective analysis was conducted of the paediatric cardiology database (Microsoft 
Access 2003) and patient records at the Chris Hani Baragwanath Academic Hospital. All 
children who had transcatheter PDA closure at Chris Hani Baragwanath Hospital between 
January 1993 and July 2008 were included (a fifteen year period).  
2.3 Procedure 
2.3.1 Implantation details 
After obtaining informed consent, the children were sedated, and femoral arterial and 
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venous access was obtained. Transcatheter PDA closure was undertaken following 
standardised procedures, outlined below and described in full elsewhere
(16)
. A descending 
aortogram in the lateral position was performed at the start of each catheterisation in order 
to measure the dimensions of the PDA. This was done to prevent any interference with the 
PDA that may cause constriction and inaccurate measurements. A full diagnostic 
catheterisation was performed in all patients prior to attempted PDA occlusion, and the 
shunt and pulmonary vascular resistance were calculated. The narrowest point and ampulla 
were routinely measured and these factors were used to select an appropriate device. With 
experience, and particularly for Amplatzer™ devices, additional measurements were 
added; these usually included the length of duct and diameter of the aorta just proximal to 
the duct (in smaller children). The size of device was based on the manufacturer’s 
recommendation of at least 2 mm greater than the narrowest point
(21)
, other factors were 
considered including, PDA shape, ampulla size, and the size of the aorta. For sizing of the 
coils the narrowest point is also used and a coil with a diameter twice the narrowest 
measurement is chosen. Coils also have a variable number of loops, the number of loops 
chosen depends on the space available in the ampulla of the PDA to pack the coils
(22)
. 
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Reorder 
Number 
Device 
Diameter at 
Descending 
Aorta (mm) 
Device 
Diameter at 
Pulmonary 
Artery (mm) 
Retention 
Skirt 
Diameter 
(mm) 
Device 
Length (mm) 
Min. Recommended 
Sheath Size 
(AMPLATZER™™ 
TorqVue™ Delivery 
System) 
9-PDA-003 5 4 9 5 5 F; 180° Curve 
9-PDA-004 6 4 10 7 6 F; 180° Curve 
9-PDA-005 8 6 12 7 6 F; 180° Curve 
9-PDA-006 10 8 16 8 6 F; 180° Curve 
9-PDA-007 12 10 18 8 7 F; 180° Curve 
Figure 2.1:Amplatzer Duct Occluder 1 Dimensions and sizing chart
(23)
 
 
Amplatzer™ devices were routinely delivered from the pulmonary side, except in one 
patient with an interrupted inferior vena cava, where an Amplatzer™ Duct Occluder II was 
placed from the aortic side. The majority of coils were delivered from the aortic side; 
however, if multiple coils were placed in a duct they were sometimes placed from the 
pulmonary side or even using a combination of aortic and pulmonary routes. 
Following device placement and prior to release we performed a number of checks to 
assess the correct placement of the device. A descending aortogram was performed on each 
patient. Pressure gradients in the aorta across the newly closed PDA were performed to 
ensure there was no significant obstruction to flow in the descending aorta. Once sure that 
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the device was correctly positioned it was released. A repeat angiogram was done and a 
gradient measured to assess any change in position during release. Following the procedure 
the patients were observed in the ward. Depending on the day the catheterisation was 
performed the follow up echocardiography took place 24 – 48 hours after the procedure. If 
there were no significant problems the children were discharged after the echocardiogram. 
2.4 Data / Study variables: 
2.4.1 Data collection: 
Data was collected from patient files and the electronic Paediatric Cardiology database 
(Microsoft Access 2003) at the Chris Hani Baragwanath Academic Hospital. Data 
collection included reviewing all available angiograms and classifying the shape of the 
PDA using the Krichenko classification
(24)
 as this had not been routinely done. 
A numbered, data collection sheet (Appendix) was completed for each patient. Data was 
then entered into a Microsoft Excel spread sheet and, for statistical analysis this was 
exported into Intercooled Stata 8.0 (Stata Corporation, College Station, TX, USA). 
2.4.2 Study variables 
Age, gender and anthropometric data were used to describe the demographic profile of 
patients with PDAs in our setting. Clinical details, haemodynamic data, anatomical details 
including PDA shape and dimensions at echocardiogram and angiography were used to 
fully describe the PDA and resultant haemodynamics. In order to assess the time taken to 
close the PDA the fluoroscopy time for each procedure was captured where possible. 
The shape of each PDA was assessed angiographically by reviewing each angiogram and 
classifying them according to the Krichenco classification (A1-3, B1-3,C1-3,D,E )
(24)
.  
11 
 
 
Figure 2.2: Krichenko Classification of PDA shape
(24)
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Figure 2.2: Lateral angiogram of type E PDA connecting descending aorta and pulmonary arteries. 
 
A successful procedure was defined as one where the PDA was closed immediately or one 
where closure occurred within one year after the procedure without any further 
intervention or procedure to effect closure. The inclusion of PDAs that close later is due to 
the fact that complete closure of the PDA by a device relies in part on thrombosis and 
formation of an intimal layer over the device that can take several months. Most are 
expected to close by one year. Failure of closure after implantation of a device implies that 
a second procedure was needed to effect closure such as a second device, another type of 
device or surgery. 
An abandoned procedure is one where a catheterisation is performed with the intention to 
close but the PDA is deemed unsuitable and the patient is sent for surgical closure without 
further attempt made to close the PDA percutaneously. 
Complications of the procedure are divided into major or minor. The division into these 
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groups was guided by the work of Vitello R et al 
(25)
. Major complications include device 
embolization, obstruction of the aorta and/or pulmonary arteries by a device requiring any 
intervention or resulting in long-term morbidity. Minor complications are defined as mild 
obstruction of the aorta or pulmonary arteries not requiring intervention, problems at the 
access site such as bleeding, need for a transfusion, haematoma formation or diminished 
perfusion to the limb requiring a heparin infusion, but which have no long term sequelae. 
2.5 Statistics and Data analysis 
Data is described using mean and ±SD, and where necessary median and inter quartile 
range. The χ2 test was used to compare categorical variables and the Student’s t-test was 
used to compare nominal variables. A P value of 0.05 was used to determine whether 
findings could have resulted by chance, with values <0.05 being interpreted as significant. 
The statistical program, Intercooled Stata 8.0 (Stata Corporation, College Station, TX, 
USA) was used.  
2.6 Ethics Approval 
Ethics approval for this study was obtained from the Ethics Committee of the University of 
the Witwatersrand, Johannesburg, South Africa (Protocol number – M070470). 
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Chapter 3 - Results 
3.1 Patient Characteristics 
Over the 15 year study period, 1254 PDAs were diagnosed, of which 293 required an 
intervention to effect closure. Surgical ligation was performed on 167 children and 139 
children underwent transcatheter closure. The demographics of the children who had 
transcatheter PDA closure are detailed in table 3.1 below.  
No differences were detected in patient characteristics between the patients who had their 
PDA closed with an Amplatzer™ device and those who had coiling of their PDA. Two 
thirds of the study patients were female, which concurs with what is commonly found in 
isolated PDA
(26)
. The majority of patients who had PDA closures were more than six 
kilograms. The anthropometric variables between those who had an Amplatzer™ device or 
Coils to close their PDA were similar. Amplatzer™ devices were occasionally used in 
children less than six kilograms even though the product guidelines recommend use only in 
children above this weight
(21)
. 
Table 3.1: Patient Characteristics 
 Variable Total Patients 
(n=139) 
Coils 
(n=101) 
Amplatzer™ 
Devices(n=49) 
P 
 
D
e
m
o
g
ra
p
h
ic
s
 
Age: median 
years (IQR) 
1.8    (1-4.5) 1.8(1.0-4.4) 2.1(1.1-4.5) 0.47
 
Sex:  %(n/N) 
Female 
 
 
Male 
 
66.2%(92/139) 
 
 
33.8%(47/139) 
 
68.3%(69/101) 
 
63.3% (31/49) 
0.54 
 
31.7%(32/101) 
 
36.7% (18/49) 
Weight (kg): 
mean (SD) 
12.8 ± 7 13.1± 8.1 12.9± 9.6 0.87 
< 6kg 5.4% (7/130) 5.3% (5/95) 4.4% (2/45)  
>6kg 94.6%(123/130) 94.7% (90/95 95.6% (43/45) 0.84 
Height (cm): 
mean (SD) 
87.4 ± 22.9 87.0±23 89.2±24.3 0.62 
Footnote: Where N in the cells is lower than the N in the header it is due to missing data. Also the total of coils and Amplatzer devices is 
more than the number of patients as in some instances more than one device in a particular patient. 
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3.2 Patent ductus arteriosus characteristics 
3.2.1 Size and shape: 
The average PDA size at its narrowest point was 3.2 mm (Standard deviation = 1.6). There 
is a difference in the mean size of coiled PDAs (2.6 ± 1.1) when compared to those closed 
with the Amplatzer™ device (4.0±1.9: mean difference=1.3, 95% CI=0.8-1.8). The 
majority of PDAs less than 2.5 mm were closed with Coils and the PDAs larger than 2.5 
mm were more likely to be closed with the Amplatzer™ device. 
Krichenco type A PDAs dominated, accounting for 72.8%, with type E the next most 
frequent at 17.6%.  In contrast to Krichenco’s description where type B was the second 
commonest shape
(24)
, it was the least common type in our population. The table below 
describes the size and shapes of the PDA’s in detail. 
Table 3.2: Characteristics of Patent Ductus Arteriosus in study population 
Var. 
cat 
Variable Total Patients 
(n=139) 
Coils  
(n=101) 
Amplatzer™ 
Devices (n=49) 
P 
 
P
D
A
 S
iz
e
 
Narrowest 
point mean 
(sd) 
3.2 ± 1.6 2.6 ± 1.1 4.0±1.9 
<0.001 
<2.5 mm % 
(n/N) 
37.5% (42/112) 47.8% (33/69) 21.7% (10/46) 
0.005 
≥2.5 mm % 
(n/N) 
62.5% (70/112) 52.2% (36/69) 78.3% (36/46) 
P
D
A
 S
h
a
p
e
 
A % (n/N) 72.8% (91/125) 74.1% (63/85) 72.9% (35/48) 
0.82 
B % (n/N) 1.6% (2/125) 2.4% (2/85) 2.1% (1/48) 
C % (n/N) 5.6% (7/125) 3.5% (3/85) 8.3% (4/48) 
D % (n/N) 2.4% (3/125) 2.4% (2/85) 2.1% (1/48) 
E % (n/N) 17.6% (22/125) 17.7% (15/85) 14.6% (7/48) 
Var. cat variable category. Sd standard deviation 
Footnote: Where N in the cells is lower than the N in the header it is due to missing data. Also the total of coils and Amplatzer devices is 
more than the number of patients as in some instances more than one device in a particular patient. 
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3.2.2 Haemodynamics and Fluoroscopy time: 
The haemodynamic measurements of these PDA’s revealed a significant mean left to right 
shunt with a Qp:Qs of  2:1 (SD± 1.2). The mean pulmonary vascular resistance was 2.1 
Woods Units (SD ± 1.8), with a pulmonary to systemic pressure ratio of 0.39±0.2. The 
chest x-rays showed cardiomegaly in 85.4% of the patients with plethoric lung fields noted 
on only 66.2% of the x-rays. Significant differences were noted when the haemodynamic 
factors between those closed with coils and those closed with Amplatzer™ devices were 
compared. The details are described in the table below, in summary the PDA’s where 
Amplatzer™ devices were used were bigger with larger shunts and higher pulmonary: 
systemic pressure ratios. Interestingly the differences in pulmonary vascular resistance and 
left atrium to aorta ratio were not significant. 
Table 3.3: Haemodynamic measurements and comparison between coil and Amplatzer group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Var. cat variable category, * mean (SD) 
Footnote: Where N in the cells is lower than the N in the header it is due to missing data. Also the total of coils and Amplatzer devices is 
more than the number of patients as in some instances more than one device in a particular patient. 
 
Fluroscopy time was recorded for each procedure where possible. Unfortunately in about 
one third of the patients it was not recorded. The mean fluoroscopy time was 27.6 minutes 
Var. 
cat 
 Variable  Total Patients 
(N=139) 
 Coils 
(N=101) 
 Amplatzer™   
Devices (N=47) 
P 
 
C
X
R
 
 Cardiomegaly % 
(n/N) 
85.4%  
(111/130) 
80.2%   
(73/91) 
93.6%              
(44/47) 
0.04 
 Plethora %     
(n/N) 
66.2%    
(86/130) 
56.0%   
(51/91) 
83.0%              
(39/47) 
0.002    
H
a
e
m
o
d
y
n
a
m
ic
s
 
 Pulse Pressure 
(mmHg):*   
46.6±9.6 44.9±10 48.8±8.5 0.03 
LA:AO:*  1.6±0.4 1.6±0.4 1.7±0.4 0.5 
 Shunt (Qp:Qs):*  2.0±1.2 1.8±0.8 2.5±1.6 0.0003 
Pulmonary 
Resistance  
(Woods units):* 
2.1±1.8 2±1.9 2.2±1.6 0.5 
 Pulmonary 
Pressure: 
Systemic 
Pressure Ratio* 
0.39±0.2 0.4±0.1 0.5±0.2 0.0005 
17 
 
for the procedures where it was recorded. With the shortest procedure taking eight and a 
half minutes and the longest two hours and 27 minutes. 
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3.3 Procedure and patient outcomes  
3.3.1 Combined outcome 
During the period under study two groups of transcatheter devices were available in our 
setting, the COOK® Coils and the Amplatzer™ duct occluders. A total of 150 
transcatheter procedures were performed on 139 patients with the intention of closing their 
PDAs. 
The procedure success rate for closing PDA’s at the first procedure over the fifteen years 
was 82% (114/139), with 15.8% (22/139) requiring further intervention and 2.2% (3/139) 
no data/unknown.  
 
Figure 3.1: Graph describing outcome of first procedure 
Footnote: The red block (n=17)on top of the success column indicates those PDAs where the ultimate result was a success for the patient 
– but they did not fit the definition of success defined by this study. 
 
Breakdown of failures: 
Failure was defined as any patient requiring a second procedure to effect closure. However 
these patients went on to receive further treatment. Of the twenty two patients who had a 
failed initial procedure, two were lost to follow up, in six patients coil occlusion was not 
possible at catheterisation and they were sent for surgical closure, two Amplatzer™ 
0
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80
100
120
Success Failure Unknown
97 
22 
3 
17 
Closed after 1 year or tiny residual PDA (17/red block) 
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patients had a similar fate. Twelve of the 22 had a second catheterisation to try to close the 
PDA, eight were successfully closed with a device at that catheterisation and the other four 
were haemodynamically insignificant and it was decided to watch them.  
 
Figure 3.2: Outcome of initially failed procedures 
 
Overall success rate if patients final outcome is considered is 92,67% (139/150), with the 
other 11 having unknown outcomes. No patients, where closure was attempted, were 
knowingly left with a significant residual PDA. 
3.3.2 COOK® Coils: 
One hundred and one COOK® coils were placed in 93 patients that underwent 
transcatheter PDA closure. In the majority of patients a single coil was used to close the 
PDA, however in larger PDA’s (before the Amplatzer™ devices were available) more than 
one coil was sometimes required to occlude the PDA. The outcomes of the patients who 
had their PDA coiled are detailed in figure 3.3 below. 
In 74 of these a single coil was used and 18 required more than one coil at their initial 
procedure. (13 patients had two coils placed at the initial procedure; four patients had three 
coils at their first procedure and in one patient four coils were used to close the PDA). 
Failures 
22  
Closed 
16  
Haemodynamically 
insignificant residual PDA 
4  
Lost to folow up 
2  
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There was a residual PDA that required further intervention in 7 patients, 6 of these 
required one further procedure and one required two further procedures.  
In 78% of patients the PDA was successfully closed with one or more coils. 7% required 
surgical closure, 5% had a small residual PDA that did not require surgical closure, one 
PDA was noted to have closed spontaneously at follow up, and eight patients were lost to 
follow up. 
 
Figure 3.3: Flow chart describing the patients who had PDA coiling and their outcome 
 
3.3.3 Amplatzer™ devices: 
A total of 49 Amplatzer™ devices were used in 46 patients. Three different Amplatzer™ 
occlusion devices were used during the study period. The Amplatzer™ devices used 
comprised of the Amplatzer™ Duct Occluder 1 which was used in 37 patients with the 
Amplatzer™ Vascular plug being used in eight patients, and a device that only became 
available towards the end of the study period, the Amplatzer™ Duct Occluder 2 being used 
in one patient. 
 
 
Coils 
n=92 
Single Coil n=74 
Successfully Deployed 
n=69 
Closed 51 
Repeat Cath 8 
Residual Flow 4 
Lost to follow-up 6 
Unsuccessful 
n=5 
Surgery 2 
Lost to follow-up 1 
Closed Spontaneously 1 
Tiny Residual PDA 1 
Multiple Coils n=18 
Successfully Deployed 
n=12 
Closed 12  
Unsuccessful 
n=6 
Surgical closure 4 
Repeat cath 1 
Lost to Follow-up  
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Figure 3.4: Algorithm describing patients who had PDA closure with an Amplatzer device 
  
Transcatheter closure was successful in 91% of the patients where an Amplatzer™ device 
was used. In 2 patients surgical closure was needed and in one patient a tiny residual PDA 
was present that did not require closure. 
The outcomes for the PDA’s closed with the Amplatzer devices were better than those in 
which the Coils were used. We achieved a success rate of 91.84% with the Amplatzer™ 
devices and 79.35% with Coils. 
 
 
 
 
 
 
 
 
Amplatzer 
Devices 
(n=46 ) 
ADO 1 
n=37 
Successfully 
Deployed n=35 
Closed 35 
Unsuccessful  
n=2 
Surgical closure 1 
Repeat cath 1 
AVP 
n=8 
Successfully Deployed n =7 
Closed 6                                    
Tiny residual 1 
Unsuccessful n=1 
Surgical Closure 
1 
ADO2 
n=1 
Unsuccessful n=0 
Successfully 
Deployed 
n = 1 
Closed 1 
ADO1 : Amplatzer Duct Occluder 1 
AVP: Amplatzer Vacsular Plug 
ADO2:  Amplatzer Duct cluder 2  
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Figure 3.5: Outcomes - Coil vs Amplatzer devices at first procedure 
3.3.4 Outcome and shape 
The shape of the PDA was important in determining the outcome (p=<0.0001). The Type 
A and Type E PDA’s had closure rates of over 88% (88.5% and 88.9% respectively). Half 
of Type B PDA’s attempted were closed. Closure rates for the type C ducts were 28.6%, 
and No type D PDA’s were successfully closed percutaneously.  
 
Figure 3.6: Effect of PDA shape on outcome at first procedure 
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The relationship between the type of closure device chosen and the PDA shape is described 
in the table below. The majority of PDA’s closed were either Type A or Type E, The Type 
A PDA’s were closed with either coils or the ADO1. In the Type E PDA’s all available 
devices were tried at least once during the study period. The Amplatzer Vascular Plug was 
used in a large proportion of the Type C PDA’s (43%). After the Amplatzer devices 
became available coils were no longer used in the Type C PDA’s. To few Type B, C and D 
PDA’s were closed to comment on their outcomes. 
Table 3.4: Device usage for each PDA shape at initial procedure 
 A B C D E P 
 Coil   
n/N (%) 
59/91  
(65%) 
1/2   
(50%) 
3/7      
(43%) 
2/3     
(66.6%) 
15/22            
(68%) 
 
 ADO 1 
n/N (%) 
32/91  
(35%) 
1/2   
(50%) 
1/7      
(14%) 
- 2/22                
(9%) 
 
 AVP   
n/N (%) 
- - 3/7          
(43%) 
1/3     
(33.3%) 
4/22              
(18%) 
 
 ADO 2 
n/N (%) 
- - - - 1/22                
(5%) 
0.003  
 
 
 
 
 
 
 
 
 
 
 
 
24 
 
3.3.5 Time to complete closure 
Over ninety per cent of the Amplatzer™ devices had completely closed the PDA within 1 
week of placement, compared to just over fifty per cent closure for coils in the first week 
(p= <0.0001). This graph only includes the PDA’s that were documented on 
echocardiography to be completely closed. 
 
Figure 3.7: Time to complete closure 
Footnote: Only PDA’s in which closure was confirmed on echocardiography are included. 
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3.3.6 Changes over time 
The Amplatzer™ device as an option to close the PDA at Chris Hani Baragwanath 
Academic Hospital rapidly became the preferred device with the drop in number of coils 
used mirroring the increase in Amplatzer™ devices.  
These changes were noted in a number of different ways that are described below. 
Device Usage: 
 
Figure 3.8: Device usage changes over time 
A repeat procedure was required when the first procedure was unsuccessful, this could be 
that percutaneous closure failed, or there was a residual shunt requiring further 
intervention. The graph below includes all patients who had repeat procedures, including 
those who initially had surgery and then went for transcatheter closure. The number of 
patients who had to undergo a second procedure decreased steadily over the fifteen years 
except for a slight increase following the introduction of the Amplatzer™ device. The 
increase was short lived, and likely due to the learning curve related to the introduction of 
a new device. The downward trend was soon resumed.  
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Repeat Procedures: 
 
Figure 3.9: Number of patients requiring a repeat procedure to close the PDA 
Footnote: This graph includes patients who initially had surgery and then went for transcatheter closure. 
 
There were a total of twenty-eight repeat procedures. Eight patients had had surgery and 
then underwent cardiac catheterisation to close a residual PDA. Six patients after failed 
transcatheter coil placement were sent for surgical ligation. Two patients where an 
Amplatzer device closure was attempted were subsequently sent for surgery. 
Twelve patients had a repeat catheterisation to close the PDA. Ten of these patients had 
coils placed initially and needed a repeat catheterisation to close the PDA, six of these 
were closed with another coil, two with an ADO, one was left with a tiny PDA, and one 
was lost to follow up. The other two patients had Amplatzer™ devices and required 
another catheterisation. The first was a child in whom an Amplatzer Vascular Plug (AVP) 
was placed and there was a tiny residual shunt – we attempted to put a coil inside the AVP, 
this was unsuccessful but as the residual PDA was so small and insignificant no further 
intervention was undertaken. In one patient there was a gradient in the DAO pre release 
and the procedure was abandoned, it was later successfully closed with a smaller device.  
Waiting Times: 
The waiting time from diagnosis to closure procedure is illustrated in the graph below, the 
median waiting time was between twenty to thirty weeks up until the time the Amplatzer 
0
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devices were introduced. Following their introduction the waiting time dropped to a 
median of less than ten weeks. 
 
Figure 3.10: Median waiting time in weeks over the study period 
Footnote: Waiting time is defined as time from diagnosis to first procedure. 
 
Surgical PDA ligation: 
 
 
Figure 3.11: Number of PDA's ligated per year over the study period 
 
 
The number of patients having their PDA ligated decreased over the fifteen-year period.  
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3.3.7 Complications: 
Three out of one hundred and forty five patients had a major complication (2%). All three 
have done well and at last follow up have no problems related to the complication.  
The first case was noted to have a significant left pulmonary artery obstruction post PDA 
occlusion. The patient was sent for surgery, the PDA was ligated and the device removed.  
The second patient developed complete heart block during the procedure following a burst 
Berman balloon. Atropine was given, a supraventricular tachycardia (SVT) followed which 
did not respond to atropine but following DC cardioversion sinus rhythm resumed. The 
PDA was then successfully closed.  
The final patient had unusual PDA anatomy with a Kommeral diverticulum, the PDA was 
closed successfully but on a CT angiogram done after the closure a vascular ring was 
noted. At last follow up the child was well and asymptomatic. 
Minor complications were noted in twenty-seven of one hundred and forty five patients 
(18.6%). None of these resulted in any permanent problems.  
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Table 3.5: Complications at first procedure relating to PDA shape 
 Minor Complications              
n/N(%) 
Major Complications             
n/N(%) 
A 13/90 (14.44%) 2/90(2.22%) 
B 0 /2(0%) 0/2 (0%) 
C 1/7 (14.29%) 1/7(14.29%) 
D 0/3 (0%) 0/3(0%) 
E 5/22 (22.73%) 0/22 (0%) 
 P=0.755 P=0.302 
 
There is no significant difference in the occurrence of either minor or major complications 
when related to the PDA shape. 
 
 
  
 
Minor Complications: 
LV Dysfunction n = 8 
Diminished Leg perfusion n=2 
Arrythmias n =3  
Haemolysis 
Embolisation 
Coils n=6 
Ampatzer n=1 
Obstruction 
Aorta n=2 
Coil n=1 
Amplatzer n=1 
Pulmonary Arteries n=6 
Coils n=6 
 
 
Minor Complications: 
LV Dysfunction n = 8 
Diminished Leg perfusion n=2 
Arrythmias n =3  
Haemolysis 
Embolisation 
         Coils n=6 
         Amplatzer n=1 
Obstruction 
         Aorta n=2 
Coil n=1 - mild gradient to watch 
Amplatzer n=1 – removed smaller 
device placed  
Pulmonary Arteries n=6 
Coils n=1 – coil removed 
Amplatzer n=5– mild gradients to 
watch 
 
 
Major Complications: n=3/145  (2%) 
LPA obstruction -   
50mmHg 
 PDA 10mm 
ADO1  16/14   
Surgically removed 
PDA Ligated – No long term sequelae 
 
Complete Heart Block –  
Burst  Berman Balloon 
 Required Atropine – SVT –
 Adenosine – cardioversion 
PDA closed –no long term sequelae 
 
PDA successfully closed  
Abnormal aortic arch and vascular ring 
(diagnosed post procedure on CT angio). 
Remains asymptomatic 
 
Figure 3.12: Details of complications 
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Chapter 4 - Discussion 
This study shows that Transcatheter occlusion of PDA is safe and effective in our setting. 
The introduction of the Amplatzer™ devices at Chris Hani Baragwanath Academic 
Hospital has increased the potential for the safe and effective closure of a wider spectrum 
of PDAs at the facility. This has diminished markedly the need for surgical closure of the 
patent ductus arteriosus.  The study also demonstrates that the size and shape of the PDA 
are both important considerations in choosing the appropriate closure device. 
The findings of our study are compared to a large review of PDA closure in general, and 
then to a review of closure using only Amplatzer devices. In 2006 Galal et al presented a 
review of original work on PDA occlusion between 1995 and 2004 found in an extensive 
online search – “We reviewed a total of 21 manuscripts, which described more than 2796 
patients.”(4) Comparing our results to those reported in this review by Galal et al, our early 
closure rates are below those reported elsewhere, but late closure approximates their 
reported range. It is important to note that, Galal et al noted immediate complete occlusion 
at angiography ten minutes after implantation. This is different to the definition we used. 
The definition of early complete occlusion in our study was based on the echocardiogram 
done within 48 hours of the procedure. The echocardiogram could be either done within 24 
hours if the procedure was done on our Thursday list or within 48 hours if done on the 
Monday list. There are likely differences in the sensitivity of the different techniques and 
the extra time to assessment in our patients gives the duct longer to close. However from a 
practical point of view, the extra 24 – 48 hours is unlikely to make any real difference to 
the patient. The “late occlusion” is a more important factor as failure to close may result in 
further procedures to close the PDA and an on going risk of endocarditis
(27)
. The rate of 
device embolization in our facility is also acceptable, falling between the highest and 
lowest rates reported in the Galal review. Notably however, our fluoroscopy time is longer 
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than all the results they report. This is likely due to multiple reasons. Firstly, we perform a 
full diagnostic catheterisation prior to closing the PDA, while in some other settings a 
more focused catheterisation is done to just close the duct. Secondly, the introduction of a 
new device (Amplatzer) also required a considerable learning curve of the catheterization 
team, prolonging the procedure for the initial patients. Finally Chris Hani Baragwanath 
Academic Hospital is a nationally accredited Paediatric Cardiac training centre, with a high 
turnover of trainees who each need to perform several procedures in order to become 
proficient, and complete their sub-speciality. As a result, these procedures almost always 
actively involved supervising and teaching trainees with little or no experience. To do this 
safely takes considerably longer.  
These results of the comparison between our site and the Galal review are shown in the 
graph below. 
 
Figure 4.1: Comparison of PDA closure with coils between our results and the review reported by Galal et al 
Footnote: Lowest – refers to lowest values in studies reviewed, and highest refers to highest values in studies reviewed 
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Figure 4.2: Comparison of PDA closure with ADO between our results and the review reported by Galal et al 
Footnote: Lowest – refers to lowest values in studies reviewed, and highest refers to highest values in studies reviewed 
 
 
In 2004, Pass published a multicentre review of closure of PDA’s with the Amplatzer™ 
Duct Occluder in the Journal of the American College of Cardiology, covering 484 patients 
from 25 centres
(28)
. The findings reported in his review are compared to those obtained in 
our study in the graphs below. Our results are very similar to those of the review, with our 
early closure rates being 92.1% and theirs 89%. Total closure rates of 97.4% were found in 
in our study, this is almost identical to the 98% in the Pass review. 
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Figure 4.3: Comparison of closure rates with the ADO between our centre and the results as reported by Pass 
et al 
The characteristics of our population and that of the Pass review are similar (e.g. age and 
weight), as are the PDA sizes and shunt ratios. Of note, as above, our fluoroscopy time is 
considerably longer, as much as three fold. The long fluoroscopy times are an important 
factor and result in increased radiation exposure to both patients and staff. Clearly, 
attention needs to be paid to strategies to reduce radiation exposure in out setting.  
Uses of these devices have also been assessed in other middle-income countries.
(8, 9)
 A 
study in Bloemfontein, confirmed the effectiveness of coils in thirty-six patients a southern 
African environment.
(17)
  
 
Figure 4.4: Comparison of PDA closure with the ADO between our centre and the results as reported by Pass 
et al 
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Shape and size of PDA are both important factors for selecting the optimal device for 
closing a particular PDA, and for closure outcome. Neither the shape nor size can be 
ignored but each PDA must be assessed individually and the most appropriate device 
chosen. To assist in the choice of correct device, a detailed angiographic assessment of the 
PDA is a necessity in preparation for transcatheter closure and has afforded the 
interventionalist the opportunity to investigate the anatomy of PDAs, which show 
remarkable variations in size and shape. These factors play an important role in deciding 
whether the PDA is amenable to transcatheter closure,
(4, 24)
 as well as in determining the 
success or failure of the intervention. Where the size of the PDA or anatomical variations 
in the shape of the PDA made successful closure unlikely, due to the lack of a suitable 
device the procedure was abandoned because the PDA was deemed unsuitable for 
transcatheter closure. It is these cases that drive the search for new devices. Careful 
measurement and assessment of the PDAs shape and size and matching the correct type 
and size of device to the individual PDA is thus essential to maximise safety and 
effectiveness as well as to minimize cost incurred by the failure of device placement or use 
of multiple devices. The practice of placing more than one coil was common in larger 
PDA’s before the availability of the Amplatzer™ devices. Bioptome assisted multiple coil 
delivery had been described during the study period but due to the availability of the 
Amplatzer devices we have not employed this technique
(29)
.  
Circumstances at Chris Hani Baragwanath Hospital differ in several important ways from 
those in high-income countries, where most studies of these devices are done. While much 
care is required in all settings to adequately allocate resources, more severe resource 
constraints in our setting make resource allocation decisions even harder. During the 
period under study our options were restricted to the detachable COOK® Flipper PDA coil 
(the device used in the early parts of the study) and the Amplatzer™ range. The use of 
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Amplatzer™ devices was first described in 1996(30), but they only became available at 
Chris Hani Baragwanath Academic Hospital in 2003. The numbers of devices that can be 
used are limited at Chris Hani Baragwanath Academic Hospital, and thus much care is 
needed in choosing the correct device, as it is not always possible to deploy a second or 
third device. In most cases failure to close the PDA at the initial procedure, necessitates 
surgical closure. This increases pressure on our already long surgical waiting list. In 
addition, the time from diagnosis to treatment of a PDA is reduced because there is no 
cardiac catheterisation waiting list at our institution. The costs incurred by the health care 
system from recurrent admissions due to complications of large PDAs in untreated children 
waiting for surgery are also likely to be reduced, but this has not been studied or 
documented. A major advantage of percutaneous closure of PDAs in our setting is that it 
removes cases from the surgical waiting list, thereby decreasing the time patients with 
other congenital heart diseases spend waiting for surgery. 
Limitations of the study 
The number of Amplatzer™ devices used is relatively small compared to other case series, 
making it difficult to draw definitive comparisons and conclusions for future practice at 
our site. Most of the patients undergoing surgery prior to the era of device closure did not 
undergo cardiac catheterisation so the data relating to PDA size and shape were not 
available for these patients, limiting the ability to compare these and later patients over 
time.  
This study is a limited in that it is a retrospective record review. While much effort was 
made to capture all data on all patients, there is still missing data.  
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Chapter 5 - Conclusions  
Transcatheter closure of the patent ductus arteriosus at Chris Hani Baragwanath Academic 
Hospital is both safe and effective. The treatment outcomes are similar to those in high-
income countries, which have considerably more resources for treating their patient 
populations. The introduction of a new device has broadened the range of PDA’s that 
could be closed and improved the closure rates over time. The size and shape of the PDA 
as noted on angiography are important to consider when choosing a device. As more 
devices become available the possibility to close a wider range of PDA’s increases. Even 
though introducing a new device is associated with a learning curve and prolonged 
fluoroscopy times, careful consideration of device shape and size and the PDA’s shape and 
size can allow for safer procedures overall and ultimately a closure of a wider range of 
PDA’s in the catheterisation laboratory. 
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Appendix 
DATA Sheet 
 
 
(mm – 2 decimal places) Actual – smallest 
(or PA end) 
Ampulla Length 
PDA size - echo    
PDA size - cath    
 
 A1-3 B1-3 C D E 
PDA classification      
 
 
 Systolic Diastolic Mean 
Systemic pressure (Asc Ao at cath)    
Pulse Pressure (mmHg) Asc Ao at cath  
LA:Ao (2 decimal places)  
Pulmonary Pressure Echo (TR Grad mmHg)  
Pulmonary Resistance R/A(2 decimal places)  
Shunt (2 decimal places)  
 Systolic Diastolic Mean 
Pulmonary pressures Cath (MPA mmHg)    
AR post closure if Y – 
Trivial, Mild, Mod, Severe 
Yes No Unknown Resolved -Y No Unk 
      
 
 AMC DN LP FM PA HN KVDD KN MD Other 
Operator/Surgeon           
 
 
 
 
 
 
Study Number  
Name (First Surname)  
Hospital number  
Sex (M or F or Unknown)  
DOB (dd/mm/yyyy)  
Weight (kg–2 decimals)  
Height (cm 1 decimal place)  
Date of Diagnosis  
Date of intervention  
Date of complete closure  
Date of discharge  
Birth weight (kg 2 decimal places)  
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Data extraction form – PDA transcatheter occlusion & Shape and Size 
 
 
 Surgery Coil Coils>1 ADO 1 ADO 2 AVP Unk 
Intervention (tick all 
that apply) 
       
Combinations – and 
description 
       
Device size 
 
 
Fluroscopy time 
(mins) 
 
 
 Success Failure Other Description of 
other 
Outcome     
 
 
 
Complications Major 
(tick) 
Yes No Unknown 
   
Complications Minor 
(tick) 
Yes No Unknown 
   
Complications - 
Details 
 
Associated lesions 
Cardiac 
 
Presenting Features 
 
 
Genetic syndrome  
CXR 
(Yes/No/Unknown) 
Cardiomegaly CTR (%) Plethora 
   
ECG 
(Yes/No/Unknown) 
RAH LAH RVH LVH 
    
Indication for 
closure 
 
 
Follow up Date Other 
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